Adaptimmune Therapeutics (NASDAQ:ADAP) Upgraded at Zacks Investment Research
Adaptimmune Therapeutics (NASDAQ:ADAP) was upgraded by Zacks Investment Research from a “hold” rating to a “strong-buy” rating in a research note issued to investors on Tuesday, Zacks.com reports. The firm currently has a $4.00 target price on the biotechnology company’s stock. Zacks Investment Research‘s price target indicates a potential upside of 16.28% from the stock’s previous close.
According to Zacks, “Adaptimmune Therapeutics plc is a biopharmaceutical company. The Company is focused on cancer immunotherapy products based on T-cell receptor platform. Adaptimmune Therapeutics plc is based in Abingdon, United Kingdom. “
Several other brokerages have also weighed in on ADAP. Leerink Swann lowered Adaptimmune Therapeutics from an “outperform” rating to a “market perform” rating and set a $4.15 price objective for the company. in a report on Tuesday, May 7th. Raymond James reduced their price objective on Adaptimmune Therapeutics from $16.00 to $6.00 and set an “outperform” rating for the company in a report on Tuesday, May 7th. ValuEngine lowered Yext from a “strong-buy” rating to a “buy” rating in a report on Friday, May 10th. Roth Capital began coverage on Tcr2 Therapeutics in a report on Friday, May 31st. They set a “neutral” rating and a $16.00 price objective for the company. Finally, Citigroup set a $14.00 price objective on Coty and gave the company a “hold” rating in a report on Thursday, May 30th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $6.59.
Adaptimmune Therapeutics (NASDAQ:ADAP) last announced its quarterly earnings data on Monday, May 6th. The biotechnology company reported ($0.24) earnings per share for the quarter, beating the consensus estimate of ($0.28) by $0.04. Adaptimmune Therapeutics had a negative return on equity of 45.03% and a negative net margin of 161.09%. On average, analysts forecast that Adaptimmune Therapeutics will post -1.17 earnings per share for the current fiscal year.
Several institutional investors have recently bought and sold shares of the company. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its position in Adaptimmune Therapeutics by 8.7% during the 1st quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 28,621 shares of the biotechnology company’s stock valued at $123,000 after acquiring an additional 2,280 shares in the last quarter. Raymond James & Associates boosted its position in Adaptimmune Therapeutics by 59.0% during the 4th quarter. Raymond James & Associates now owns 22,906 shares of the biotechnology company’s stock valued at $132,000 after acquiring an additional 8,498 shares in the last quarter. Rathbone Brothers plc boosted its position in shares of Adaptimmune Therapeutics by 27.9% in the 1st quarter. Rathbone Brothers plc now owns 285,722 shares of the biotechnology company’s stock worth $1,229,000 after purchasing an additional 62,292 shares in the last quarter. BlackRock Inc. boosted its position in shares of Adaptimmune Therapeutics by 10.4% in the 4th quarter. BlackRock Inc. now owns 856,415 shares of the biotechnology company’s stock worth $4,924,000 after purchasing an additional 81,010 shares in the last quarter. Finally, Squarepoint Ops LLC bought a new stake in shares of Adaptimmune Therapeutics in the 4th quarter worth approximately $622,000. 66.30% of the stock is owned by hedge funds and other institutional investors.
Adaptimmune Therapeutics Company Profile
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States. The company's specific peptide enhanced affinity receptor T-cell platform enables it to identify cancer targets. It is involved in developing ADP-A2M10 that is in the phase I clinical trials for the treatment of non-small cell lung cancer (NSCLC), as well as urothelial, melanoma, and head and neck cancers; ADP-A2M4 that is in phase I clinical trial for solid tumor indication that include urothelial, melanoma, head and neck, ovarian, NSCLC, esophageal, gastric, synovial sarcoma, and myxoid round cell liposarcoma cancers; and ADP-A2AFP that is in phase I clinical trial for hepatocellular carcinoma.
Featured Article: Current Ratio
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.